ADB-FUBINACA

$320.00$1,800.00

ADB-FUBINACA is a novel synthetic cannabinoid compound. Members of this group produce cannabis-like effects when administered.

Clear
Compare
SKU: N/A Category:

Description

ADB-FUBINACA

ADB-FUBINACA is a synthetic cannabinoid that has recently been identified in herbal blends.1 Its name refers to its structure, which has a 1-amino-3,3-dimethyl-1-oxobutan-2-yl (ADB) group linked to a 4-fluorobenzyl-1H-indazole-3-carboxamide (FUBINACA) base at the amide group. The physiological and toxicological properties of this compound have not been determined. This product is intended for forensic and research applications.

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013.  The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively.  ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.

An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.

Although this substance has not been formally studied, from analysis of the structure, it is presumed that AB-FUBINACA has a similar binding profile to that of other cannabinoids and matches many of the in vivo properties of Δ9-THC. AB-FUBINACA exhibits its range of effects via full agonism of both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2. However, the role of these interactions and how they result in the cannabinoid high experience continues to remain elusive.

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.

For orders above 1000g(1KG) of buy ADB-FUBINACA you should contact us on email.

 

Reviews

There are no reviews yet.

Be the first to review “ADB-FUBINACA”

Your email address will not be published. Required fields are marked *

X